glycine has been researched along with Idiopathic Parkinson Disease in 114 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " Our objective was to precisely assess changes in α-syn levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines following acute exposure to pesticides (rotenone, paraquat, maneb, and glyphosate) using Western blot and flow cytometry." | 3.79 | Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines. ( Andrieu, T; Baron, T; Bétemps, D; Chorfa, A; Hogeveen, K; Lazizzera, C; Morignat, E, 2013) |
| "Concentrations of putative neuroactive substances glutamate, aspartate, gamma-aminobutyric acid, glycine, proline and ethanolamine were determined in ventricular cerebrospinal fluid collected in patients suffering from Parkinson's disease, pain syndromes or cerebellar tremor." | 3.67 | Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders. ( Amsler, U; Cuénod, M; Perschak, H; Siegfried, J; Vischer, A, 1987) |
| " The cysteine increase may be due to the significant higher dosing of daily LD/DCI and the significant higher morning LD/DCI dose 1 hour before blood sampling in PD patients with tHcy above 15 when compared with the remaining PD patients and the controls." | 2.74 | Cysteine elevation in levodopa-treated patients with Parkinson's disease. ( Kuhn, W; Müller, T, 2009) |
| "Conversely, cataplexy, one of the key symptoms of narcolepsy, is a striking sudden episode of muscle weakness triggered by emotions during wakefulness, and comparable to REM sleep atonia." | 2.47 | The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. ( Clément, O; Fort, P; Gervasoni, D; Léger, L; Luppi, PH; Peyron, C; Salvert, D; Sapin, E, 2011) |
| " So far it is not clear whether NMDA receptor antagonists including glycine antagonists would be suitable for chronic administration because of their effects on cognition, learning and motor function." | 2.40 | The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. ( Dannhardt, G; Kohl, BK, 1998) |
| "All cancers combined, nonskin cancers, smoking-related cancers, hormone-related cancers, and other types of cancer." | 1.42 | Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis. ( Aasly, J; Agalliu, I; Bressman, S; Friedman, E; Giladi, N; Hassin-Baer, S; Inzelberg, R; Marti-Masso, JF; Mirelman, A; Orr-Urtreger, A; Ruiz-Martinez, J; San Luciano, M; Saunders-Pullman, R; Waro, B, 2015) |
| "Patients with Parkinson's disease have reduced gray matter volume and fractional anisotropy in both cortical and sub-cortical structures, yet changes in the pre-motor phase of the disease are unknown." | 1.40 | A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers. ( Artzi, M; Ben Bashat, D; Bloem, BR; Bressman, S; Giladi, N; Gurevich, T; Helmich, RC; Hendler, T; Jacob, Y; Marder, K; Mirelman, A; Orr-Urtreger, A; Thaler, A; van Nuenen, BF, 2014) |
| "The phenotype of Parkinson's disease (PD) in patients with and without leucine-rich repeat kinase 2 (LRRK2) G2019S mutations reportedly is similar; however, large, uniformly evaluated series are lacking." | 1.39 | Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations. ( Alcalay, RN; Bar Shira, A; Barrett, MJ; Bressman, S; Cabassa, J; Clark, L; Cote, L; Deik, A; Dorovski, T; Fahn, S; Ford, B; Gana Weisz, M; Giladi, N; Groves, M; Gurevich, T; Hunt, AL; Johannes, B; Levy, O; Louis, E; Lubarr, N; Marder, KS; Mazzoni, P; Mejia Santana, H; Miravite, J; Mirelman, A; Nichols, W; Orbe-Reilly, M; Orr-Urtreger, A; Ortega, R; Ozelius, L; Palmese, C; Pauciulo, M; Raymond, D; Roos, E; Rosado, L; Ruiz, D; Sachdev, R; San Luciano, M; Sarva, H; Saunders-Pullman, R; Severt, L; Shanker, V; Soto-Valencia, J; Swan, MC; Tang, MX; Thaler, A; Waters, C; Yasinovsky, K; Zalis, M, 2013) |
| "While Parkinson's disease (PD) phenotype in leucine-rich repeat kinase 2 gene (LRRK2)-associated and sporadic PD seems similar, there is paucity of data on the possible effect of mutations in LRRK2 on response to and complications of dopaminergic therapy." | 1.38 | Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. ( Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Rosset, S; Vituri, A; Yahalom, G, 2012) |
| "Parkinson's disease is a promising target of applying personalized medicine." | 1.38 | [The absence of the common LRRK2 G2019S mutation in 120 young onset Hungarian Parkinon's disease patients]. ( Balicza, P; Balogh, I; Bereznai, B; Dibó, G; Hidasi, E; Klivényi, P; Molnár, MJ; Takáts, A, 2012) |
| " The oral bioavailability of D-phenylglycine-L-dopa was 31." | 1.36 | Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption. ( Fan, YB; Lu, HH; Tsai, MC; Tsai, TH; Wang, CL; Wang, HP, 2010) |
| "UK Medical Research Council; UK Parkinson's Disease Society; UK Brain Research Trust; Internationaal Parkinson Fonds; Volkswagen Foundation; National Institutes of Health: National Institute of Neurological Disorders and Stroke and National Institute of Aging; Udall Parkinson's Disease Centre of Excellence; Pacific Alzheimer Research Foundation Centre; Italian Telethon Foundation; Fondazione Grigioni per il Morbo di Parkinson; Michael J Fox Foundation for Parkinson's Research; Safra Global Genetics Consortium; US Department of Veterans Affairs; French Agence Nationale de la Recherche." | 1.35 | Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. ( Aasly, J; Berciano, J; Bhatia, KP; Bonifati, V; Bressman, S; Brice, A; Durr, A; Falchi, M; Ferreira, JJ; Gasser, T; Goldwurm, S; Healy, DG; Kay, DM; Klein, C; Lang, AE; Lees, AJ; Lynch, T; Marras, C; O'Sullivan, SS; Schapira, AH; Tolosa, E; Williams, DR; Wood, NW; Wszolek, ZK; Zabetian, CP, 2008) |
| "The mean age at onset for parkinsonism was 60 years, range 30-79 years; fewer than 20% of the patients had symptoms before the age 50 years, while by 75 years >90% of them had developed symptoms." | 1.35 | Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease. ( Benecke, R; Berg, D; Bonifati, V; Brown, L; Cras, P; De Deyn, PP; Engelborghs, S; Farrer, MJ; Foroud, T; Gaig, C; Gasser, T; Gibson, JM; Goldwurm, S; Guidi, M; Hagenah, J; Haugarvoll, K; Kachergus, JM; Klein, C; Nichols, WC; Nuytemans, K; Pals, P; Pickut, B; Rademakers, R; Riboldazzi, G; Ross, OA; Samii, A; Tan, EK; Theuns, J; Tolosa, E; Uitti, RJ; Van Broeckhoven, C; Walter, U; Wszolek, ZK; Zabetian, CP, 2008) |
| " Comparisons between individuals with heterozygous and homozygous LRRK2 mutations suggested that gene dosage was not correlated with phenotypic differences; however, the estimated penetrance was greater in homozygotes across all age groups." | 1.34 | Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families. ( Akkari, PA; Amouri, R; Ben Sassi, S; Ben Yahmed, S; Burn, DJ; El Euch-Fayeche, G; Elango, R; Freeman, A; Gibson, RA; Gouider-Khouja, N; Hattori, N; Hentati, F; Hunter, C; Ishihara, L; Jankovic, J; Kefi, M; Leppert, D; Lyons, K; Middleton, L; Nance, M; Pahwa, R; Ragone, L; Reeves, KH; Surh, L; Swartz, JE; Thomas, S; Warren, L; Watts, RL; Wielinski, C; Zouari, M, 2007) |
| "Parkinson disease related to LRRK2 is characterized by typical clinical features, and the similarities between patients with homozygous and heterozygous mutations do not support a gene dosage effect." | 1.33 | Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. ( Amouri, R; Brice, A; Dürr, A; Farrer, MJ; Foroud, TM; Gibson, R; Griffith, A; Hattori, N; Hentati, F; Ishihara, L; Leppert, D; Lesage, S; Middleton, L; Nichols, WC; Tazir, M; Uitti, RJ; Warren, L; Watts, R; Wszolek, ZK; Zabetian, CP, 2006) |
| "The R1441G mutation causes a form of Parkinson's disease that is equivalent to that observed in idiopathic Parkinson's disease." | 1.33 | Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. ( López de Munain, A; Martí-Massó, JF; Martínez-Gil, A; Paisán-Ruiz, C; Pérez-Tur, J; Ruiz-Martínez, J; Sáenz, A; Sánchez-Mut, JV; Simón-Sánchez, J; Singleton, AB, 2006) |
| "A total of 956 individuals with Parkinson's disease (PD) from 430 multiplex PD pedigrees were screened for 12 previously reported, pathogenic LRRK2 mutations: R793M, L1114L, I1371V, R1441C, R1441G, R1441H, Y1699C, M1869T, I2012T, I2020T, G2385R, and IVS31 +3G > A." | 1.33 | Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease. ( Elsaesser, VE; Foroud, T; Halter, CA; Marek, DK; Nichols, WC; Pankratz, N; Pauciulo, MW; Rudolph, A; Shults, CW, 2006) |
| "The Unified Parkinson's disease rating scale (UPDRS) was also completed." | 1.32 | Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece. ( Athanassiadou, A; Ellul, J; Papadimitriou, A; Papapetropoulos, S; Papapetropoulos, T; Paschalis, C, 2003) |
| "In the search for a therapy of Parkinson's disease, ionotropic, mainly NMDA, receptor antagonists were found to have moderately beneficial, yet also some undesirable side-effects." | 1.31 | The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity. ( Konieczny, J; Lorenc-Koci, E; Ossowska, K; Pilc, A; Wolfarth, S, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (7.02) | 18.7374 |
| 1990's | 9 (7.89) | 18.2507 |
| 2000's | 55 (48.25) | 29.6817 |
| 2010's | 37 (32.46) | 24.3611 |
| 2020's | 5 (4.39) | 2.80 |
| Authors | Studies |
|---|---|
| Zagare, A | 1 |
| Barmpa, K | 1 |
| Smajic, S | 1 |
| Smits, LM | 1 |
| Grzyb, K | 1 |
| Grünewald, A | 1 |
| Skupin, A | 1 |
| Nickels, SL | 1 |
| Schwamborn, JC | 1 |
| Fujimaki, A | 1 |
| Ohuchi, K | 1 |
| Takizawa, S | 1 |
| Murakami, T | 1 |
| Kurita, H | 1 |
| Hozumi, I | 1 |
| Wen, X | 1 |
| Kitamura, Y | 1 |
| Wu, Z | 1 |
| Maekawa, Y | 1 |
| Inden, M | 1 |
| Egger, F | 1 |
| Jakab, M | 1 |
| Fuchs, J | 1 |
| Oberascher, K | 1 |
| Brachtl, G | 1 |
| Ritter, M | 1 |
| Kerschbaum, HH | 1 |
| Gaisberger, M | 1 |
| Eldeeb, MA | 1 |
| Ragheb, MA | 1 |
| Yue, D | 1 |
| Zeng, C | 1 |
| Okyere, SK | 1 |
| Chen, Z | 1 |
| Hu, Y | 1 |
| Lee, AJ | 1 |
| Wang, Y | 1 |
| Alcalay, RN | 2 |
| Mejia-Santana, H | 1 |
| Saunders-Pullman, R | 6 |
| Bressman, S | 7 |
| Corvol, JC | 1 |
| Brice, A | 6 |
| Lesage, S | 5 |
| Mangone, G | 1 |
| Tolosa, E | 6 |
| Pont-Sunyer, C | 2 |
| Vilas, D | 1 |
| Schüle, B | 3 |
| Kausar, F | 3 |
| Foroud, T | 4 |
| Berg, D | 2 |
| Brockmann, K | 1 |
| Goldwurm, S | 6 |
| Siri, C | 1 |
| Asselta, R | 1 |
| Ruiz-Martinez, J | 5 |
| Mondragón, E | 2 |
| Marras, C | 5 |
| Ghate, T | 3 |
| Giladi, N | 4 |
| Mirelman, A | 4 |
| Marder, K | 2 |
| Vermilyea, SC | 1 |
| Emborg, ME | 1 |
| Mestre, TA | 2 |
| Visanji, NP | 2 |
| Connolly, BS | 2 |
| Gasca-Salas, C | 2 |
| Kern, DS | 2 |
| Jain, J | 2 |
| Slow, EJ | 2 |
| Faust-Socher, A | 2 |
| Kasten, M | 1 |
| Wadia, PM | 1 |
| Zadikoff, C | 1 |
| Kumar, P | 1 |
| de Bie, RM | 1 |
| Thomsen, T | 1 |
| Lang, AE | 4 |
| Klein, C | 6 |
| Eriguchi, M | 1 |
| Iida, K | 1 |
| Ikeda, S | 1 |
| Osoegawa, M | 1 |
| Nishioka, K | 1 |
| Hattori, N | 3 |
| Nagayama, H | 1 |
| Hara, H | 1 |
| Creed, RB | 1 |
| Menalled, L | 1 |
| Casey, B | 1 |
| Dave, KD | 1 |
| Janssens, HB | 1 |
| Veinbergs, I | 1 |
| van der Hart, M | 1 |
| Rassoulpour, A | 1 |
| Goldberg, MS | 1 |
| Heresco-Levy, U | 1 |
| Shoham, S | 1 |
| Javitt, DC | 1 |
| Chorfa, A | 1 |
| Bétemps, D | 1 |
| Morignat, E | 1 |
| Lazizzera, C | 1 |
| Hogeveen, K | 1 |
| Andrieu, T | 1 |
| Baron, T | 1 |
| Mamais, A | 1 |
| Raja, M | 1 |
| Manzoni, C | 1 |
| Dihanich, S | 1 |
| Lees, A | 1 |
| Moore, D | 1 |
| Lewis, PA | 1 |
| Bandopadhyay, R | 1 |
| Gao, C | 1 |
| Pang, H | 1 |
| Luo, XG | 1 |
| Ren, Y | 1 |
| Shang, H | 1 |
| He, ZY | 1 |
| Tang, MX | 1 |
| Mejia Santana, H | 1 |
| Raymond, D | 4 |
| Roos, E | 1 |
| Orbe-Reilly, M | 1 |
| Gurevich, T | 2 |
| Bar Shira, A | 1 |
| Gana Weisz, M | 1 |
| Yasinovsky, K | 1 |
| Zalis, M | 1 |
| Thaler, A | 2 |
| Deik, A | 1 |
| Barrett, MJ | 1 |
| Cabassa, J | 2 |
| Groves, M | 2 |
| Hunt, AL | 1 |
| Lubarr, N | 1 |
| San Luciano, M | 3 |
| Miravite, J | 1 |
| Palmese, C | 2 |
| Sachdev, R | 1 |
| Sarva, H | 1 |
| Severt, L | 1 |
| Shanker, V | 2 |
| Swan, MC | 1 |
| Soto-Valencia, J | 1 |
| Johannes, B | 1 |
| Ortega, R | 1 |
| Fahn, S | 1 |
| Cote, L | 1 |
| Waters, C | 1 |
| Mazzoni, P | 1 |
| Ford, B | 1 |
| Louis, E | 1 |
| Levy, O | 1 |
| Rosado, L | 1 |
| Ruiz, D | 1 |
| Dorovski, T | 1 |
| Pauciulo, M | 1 |
| Nichols, W | 1 |
| Orr-Urtreger, A | 3 |
| Ozelius, L | 3 |
| Clark, L | 1 |
| Marder, KS | 1 |
| Melamed, E | 1 |
| Artzi, M | 1 |
| Jacob, Y | 1 |
| Helmich, RC | 1 |
| van Nuenen, BF | 1 |
| Bloem, BR | 1 |
| Hendler, T | 1 |
| Ben Bashat, D | 1 |
| Chou, JS | 1 |
| Chen, CY | 1 |
| Chen, YL | 1 |
| Weng, YH | 1 |
| Yeh, TH | 1 |
| Lu, CS | 1 |
| Chang, YM | 1 |
| Wang, HL | 1 |
| Yahalom, G | 2 |
| Orlev, Y | 1 |
| Cohen, OS | 2 |
| Kozlova, E | 2 |
| Friedman, E | 3 |
| Inzelberg, R | 3 |
| Hassin-Baer, S | 3 |
| Estanga, A | 1 |
| Rodriguez-Oroz, MC | 1 |
| Barandiaran, M | 1 |
| Gorostidi, A | 2 |
| Bergareche, A | 2 |
| Lopez de Munain, A | 3 |
| Marti-Masso, JF | 3 |
| Agalliu, I | 1 |
| Waro, B | 1 |
| Aasly, J | 2 |
| Tsika, E | 1 |
| Nguyen, AP | 1 |
| Dusonchet, J | 1 |
| Colin, P | 1 |
| Schneider, BL | 1 |
| Moore, DJ | 1 |
| Cao, M | 1 |
| Gu, ZQ | 1 |
| Li, Y | 1 |
| Zhang, H | 1 |
| Dan, XJ | 1 |
| Cen, SS | 1 |
| Li, DW | 1 |
| Chan, P | 1 |
| Xu, S | 1 |
| Liu, J | 1 |
| Yang, X | 1 |
| Qian, Y | 1 |
| Xiao, Q | 1 |
| Bhudhikanok, GS | 1 |
| Udupa, K | 1 |
| AlDakheel, A | 1 |
| Kim, S | 1 |
| Azhu Valappil, R | 1 |
| Rogaeva, E | 2 |
| William Langston, J | 1 |
| Tanner, CM | 1 |
| Goldman, SM | 1 |
| Hoepken, HH | 1 |
| Gispert, S | 1 |
| Azizov, M | 1 |
| Klinkenberg, M | 1 |
| Ricciardi, F | 1 |
| Kurz, A | 1 |
| Morales-Gordo, B | 1 |
| Bonin, M | 1 |
| Riess, O | 2 |
| Gasser, T | 3 |
| Kögel, D | 1 |
| Steinmetz, H | 1 |
| Auburger, G | 2 |
| Hulihan, MM | 2 |
| Ishihara-Paul, L | 1 |
| Kachergus, J | 1 |
| Warren, L | 3 |
| Amouri, R | 3 |
| Elango, R | 2 |
| Prinjha, RK | 1 |
| Upmanyu, R | 1 |
| Kefi, M | 2 |
| Zouari, M | 2 |
| Sassi, SB | 1 |
| Yahmed, SB | 1 |
| El Euch-Fayeche, G | 2 |
| Matthews, PM | 1 |
| Middleton, LT | 1 |
| Gibson, RA | 2 |
| Hentati, F | 3 |
| Farrer, MJ | 8 |
| Healy, DG | 1 |
| Falchi, M | 1 |
| O'Sullivan, SS | 1 |
| Bonifati, V | 4 |
| Durr, A | 5 |
| Zabetian, CP | 6 |
| Ferreira, JJ | 1 |
| Kay, DM | 3 |
| Williams, DR | 1 |
| Wszolek, ZK | 3 |
| Berciano, J | 2 |
| Schapira, AH | 2 |
| Lynch, T | 2 |
| Bhatia, KP | 1 |
| Lees, AJ | 1 |
| Wood, NW | 1 |
| Elbaz, A | 1 |
| De Rosa, A | 1 |
| Criscuolo, C | 1 |
| Mancini, P | 1 |
| De Martino, M | 1 |
| Giordano, IA | 1 |
| Pappatà, S | 1 |
| Filla, A | 1 |
| De Michele, G | 1 |
| Lohmann, E | 3 |
| Leclere, L | 2 |
| De Anna, F | 1 |
| Dubois, B | 1 |
| Agid, Y | 2 |
| Patra, B | 1 |
| Parsian, AJ | 1 |
| Racette, BA | 2 |
| Zhao, JH | 1 |
| Perlmutter, JS | 2 |
| Parsian, A | 1 |
| Floris, G | 1 |
| Cannas, A | 1 |
| Solla, P | 1 |
| Murru, MR | 1 |
| Tranquilli, S | 1 |
| Corongiu, D | 1 |
| Rolesu, M | 1 |
| Cuccu, S | 1 |
| Sardu, C | 1 |
| Marrosu, F | 1 |
| Marrosu, MG | 1 |
| Zarranz, JJ | 1 |
| Gómez-Esteban, JC | 2 |
| Latourelle, JC | 1 |
| Sun, M | 1 |
| Lew, MF | 1 |
| Suchowersky, O | 1 |
| Golbe, LI | 1 |
| Mark, MH | 1 |
| Growdon, JH | 1 |
| Wooten, GF | 1 |
| Watts, RL | 2 |
| Guttman, M | 1 |
| Ahmed, A | 1 |
| Shill, HA | 1 |
| Singer, C | 2 |
| Pezzoli, G | 3 |
| Zini, M | 3 |
| Saint-Hilaire, MH | 1 |
| Hendricks, AE | 1 |
| Williamson, S | 1 |
| Nagle, MW | 1 |
| Wilk, JB | 1 |
| Massood, T | 1 |
| Huskey, KW | 1 |
| Laramie, JM | 1 |
| DeStefano, AL | 1 |
| Baker, KB | 1 |
| Itin, I | 1 |
| Litvan, I | 1 |
| Nicholson, G | 1 |
| Corbett, A | 1 |
| Nance, M | 2 |
| Drasby, E | 1 |
| Isaacson, S | 1 |
| Burn, DJ | 2 |
| Chinnery, PF | 1 |
| Pramstaller, PP | 1 |
| Al-hinti, J | 1 |
| Moller, AT | 1 |
| Ostergaard, K | 1 |
| Sherman, SJ | 1 |
| Roxburgh, R | 1 |
| Snow, B | 1 |
| Slevin, JT | 1 |
| Cambi, F | 1 |
| Gusella, JF | 1 |
| Myers, RH | 1 |
| Blekher, T | 1 |
| Weaver, M | 1 |
| Rupp, J | 1 |
| Nichols, WC | 4 |
| Hui, SL | 1 |
| Gray, J | 1 |
| Yee, RD | 1 |
| Wojcieszek, J | 1 |
| Müller, T | 1 |
| Kuhn, W | 1 |
| Yamamoto, M | 1 |
| Lopez, AN | 1 |
| Ujike, H | 1 |
| Mata, IF | 1 |
| Izumi, Y | 1 |
| Kaji, R | 1 |
| Maruyama, H | 1 |
| Morino, H | 1 |
| Oda, M | 1 |
| Hutter, CM | 1 |
| Edwards, KL | 1 |
| Schellenberg, GD | 1 |
| Tsuang, DW | 1 |
| Yearout, D | 1 |
| Larson, EB | 1 |
| Kawakami, H | 1 |
| Paus, S | 1 |
| Gadow, F | 1 |
| Knapp, M | 1 |
| Klockgether, T | 1 |
| Wüllner, U | 1 |
| Kim, JM | 1 |
| Lee, JY | 1 |
| Kim, HJ | 1 |
| Kim, JS | 1 |
| Shin, ES | 1 |
| Cho, JH | 1 |
| Park, SS | 1 |
| Jeon, BS | 1 |
| Mao, XY | 1 |
| Burgunder, JM | 3 |
| Zhang, ZJ | 3 |
| Chang, XL | 1 |
| Peng, R | 2 |
| Yang, Y | 1 |
| Wang, YC | 2 |
| Li, T | 2 |
| Gomez, A | 1 |
| Ferrer, I | 1 |
| Benamer, HT | 1 |
| de Silva, R | 1 |
| Miyake, Y | 1 |
| Tsuboi, Y | 1 |
| Koyanagi, M | 1 |
| Fujimoto, T | 1 |
| Shirasawa, S | 1 |
| Kiyohara, C | 1 |
| Tanaka, K | 1 |
| Fukushima, W | 1 |
| Sasaki, S | 1 |
| Yamada, T | 1 |
| Oeda, T | 1 |
| Miki, T | 1 |
| Kawamura, N | 1 |
| Sakae, N | 1 |
| Fukuyama, H | 1 |
| Hirota, Y | 1 |
| Nagai, M | 1 |
| Ibañez, B | 1 |
| Alzualde, A | 1 |
| Otaegui, D | 1 |
| Moreno, F | 1 |
| Martí Massó, JF | 1 |
| Wang, CL | 1 |
| Fan, YB | 1 |
| Lu, HH | 1 |
| Tsai, TH | 1 |
| Tsai, MC | 1 |
| Wang, HP | 1 |
| Yamamoto-Watanabe, Y | 1 |
| Watanabe, M | 1 |
| Jackson, M | 1 |
| Akimoto, H | 1 |
| Sugimoto, K | 1 |
| Yasujima, M | 1 |
| Wakasaya, Y | 1 |
| Matsubara, E | 1 |
| Kawarabayashi, T | 1 |
| Harigaya, Y | 1 |
| Lyndon, AR | 1 |
| Shoji, M | 1 |
| Luppi, PH | 1 |
| Clément, O | 1 |
| Sapin, E | 1 |
| Gervasoni, D | 1 |
| Peyron, C | 1 |
| Léger, L | 1 |
| Salvert, D | 1 |
| Fort, P | 1 |
| Valldeoriola, F | 2 |
| Gaig, C | 3 |
| Muxí, A | 1 |
| Navales, I | 1 |
| Paredes, P | 1 |
| Lomeña, F | 1 |
| De la Cerda, A | 1 |
| Buongiorno, M | 1 |
| Ezquerra, M | 2 |
| Santacruz, P | 1 |
| Martí, MJ | 2 |
| Brüggemann, N | 1 |
| Hagenah, J | 2 |
| Stanley, K | 2 |
| Wang, C | 1 |
| Ozelius, LJ | 1 |
| Bressman, SB | 1 |
| Heiman, G | 1 |
| Tunesi, S | 1 |
| Tesei, S | 2 |
| Sironi, F | 2 |
| Primignani, P | 1 |
| Magnani, C | 1 |
| Kaplan, N | 1 |
| Vituri, A | 1 |
| Korczyn, AD | 1 |
| Rosset, S | 1 |
| Balicza, P | 1 |
| Bereznai, B | 1 |
| Takáts, A | 1 |
| Klivényi, P | 1 |
| Dibó, G | 1 |
| Hidasi, E | 1 |
| Balogh, I | 1 |
| Molnár, MJ | 1 |
| Sierra, M | 1 |
| Sánchez-Juan, P | 1 |
| Martínez-Rodríguez, MI | 1 |
| González-Aramburu, I | 1 |
| García-Gorostiaga, I | 1 |
| Quirce, MR | 1 |
| Palacio, E | 1 |
| Carril, JM | 1 |
| Combarros, O | 1 |
| Infante, J | 1 |
| García-Lozano, JR | 1 |
| Mir, P | 1 |
| Alberca, R | 1 |
| Aguilera, I | 1 |
| Gil Néciga, E | 1 |
| Fernández-López, O | 1 |
| Cayuela, A | 1 |
| Núñez-Roldan, A | 1 |
| Poisik, OV | 1 |
| Mannaioni, G | 1 |
| Traynelis, S | 1 |
| Smith, Y | 1 |
| Conn, PJ | 1 |
| Holzmann, C | 1 |
| Krüger, R | 1 |
| Saecker, AM | 1 |
| Schmitt, I | 1 |
| Schöls, L | 1 |
| Berger, K | 1 |
| Papapetropoulos, S | 2 |
| Ellul, J | 1 |
| Paschalis, C | 1 |
| Athanassiadou, A | 1 |
| Papadimitriou, A | 1 |
| Papapetropoulos, T | 1 |
| Zekanowski, C | 1 |
| Pepłońska, B | 1 |
| Styczyńska, M | 1 |
| Religa, D | 1 |
| Pfeffer, A | 1 |
| Czyzewski, K | 1 |
| Gabryelewicz, T | 1 |
| Szybińska, A | 1 |
| Kijanowska-Haładyna, B | 1 |
| Kotapka-Minc, S | 1 |
| Łuczywek, E | 1 |
| Barczak, A | 1 |
| Wasiak, B | 1 |
| Chodakowska-Zebrowska, M | 1 |
| Przekop, I | 1 |
| Kuźnicki, J | 1 |
| Barcikowska, M | 1 |
| Hernandez, DG | 1 |
| Paisán-Ruíz, C | 2 |
| McInerney-Leo, A | 2 |
| Jain, S | 1 |
| Meyer-Lindenberg, A | 1 |
| Evans, EW | 1 |
| Berman, KF | 1 |
| Johnson, J | 1 |
| Schäffer, AA | 1 |
| Lopez, GJ | 1 |
| Nussbaum, RL | 1 |
| Singleton, AB | 2 |
| Passey, S | 1 |
| Domenici, MR | 1 |
| Potenza, RL | 1 |
| Martire, A | 1 |
| Coccurello, R | 1 |
| Pèzzola, A | 1 |
| Reggio, R | 1 |
| Tebano, MT | 1 |
| Popoli, P | 1 |
| Kramer, P | 2 |
| Higgins, D | 1 |
| Payami, H | 2 |
| Bras, JM | 1 |
| Guerreiro, RJ | 1 |
| Ribeiro, MH | 1 |
| Januario, C | 1 |
| Morgadinho, A | 1 |
| Oliveira, CR | 1 |
| Cunha, L | 1 |
| Hardy, J | 1 |
| Singleton, A | 1 |
| Ibanez, P | 1 |
| Pollak, P | 1 |
| Tison, F | 1 |
| Tazir, M | 2 |
| Leutenegger, AL | 1 |
| Guimaraes, J | 1 |
| Bonnet, AM | 1 |
| Factor, SA | 1 |
| Nutt, JG | 1 |
| Samii, A | 2 |
| Griffith, A | 2 |
| Bird, TD | 1 |
| Higgins, DS | 1 |
| Giasson, BI | 1 |
| Covy, JP | 1 |
| Bonini, NM | 1 |
| Hurtig, HI | 1 |
| Trojanowski, JQ | 1 |
| Van Deerlin, VM | 1 |
| Muñoz, E | 1 |
| Williams-Gray, CH | 1 |
| Goris, A | 1 |
| Foltynie, T | 1 |
| Brown, J | 1 |
| Maranian, M | 1 |
| Walton, A | 1 |
| Compston, DA | 1 |
| Sawcer, SJ | 1 |
| Barker, RA | 1 |
| Ossowska, K | 2 |
| Konieczny, J | 2 |
| Wardas, J | 1 |
| Pietraszek, M | 1 |
| Kuter, K | 1 |
| Wolfarth, S | 2 |
| Pilc, A | 2 |
| Ross, OA | 4 |
| Toft, M | 2 |
| Johnson, JL | 1 |
| Mash, DC | 1 |
| Ishihara, L | 2 |
| Gibson, R | 1 |
| Uitti, RJ | 2 |
| Leppert, D | 2 |
| Watts, R | 1 |
| Foroud, TM | 1 |
| Middleton, L | 2 |
| Simón-Sánchez, J | 1 |
| Sánchez-Mut, JV | 1 |
| Martínez-Gil, A | 1 |
| Sáenz, A | 1 |
| Pérez-Tur, J | 1 |
| Pchelina, SN | 1 |
| Yakimovskii, AF | 1 |
| Ivanova, ON | 1 |
| Emelianov, AK | 1 |
| Zakharchuk, AH | 1 |
| Schwarzman, AL | 1 |
| Pankratz, N | 1 |
| Pauciulo, MW | 1 |
| Elsaesser, VE | 1 |
| Marek, DK | 1 |
| Halter, CA | 1 |
| Rudolph, A | 1 |
| Shults, CW | 1 |
| Tan, EK | 5 |
| Skipper, L | 1 |
| Tan, L | 2 |
| Liu, JJ | 2 |
| Gosal, D | 1 |
| Haugarvoll, K | 3 |
| Gibson, JM | 2 |
| Deng, H | 1 |
| Le, W | 1 |
| Guo, Y | 1 |
| Hunter, CB | 1 |
| Xie, W | 1 |
| Huang, M | 1 |
| Jankovic, J | 2 |
| Lyons, K | 1 |
| Wielinski, C | 1 |
| Hunter, C | 1 |
| Swartz, JE | 1 |
| Akkari, PA | 1 |
| Surh, L | 1 |
| Reeves, KH | 1 |
| Thomas, S | 1 |
| Ragone, L | 1 |
| Pahwa, R | 1 |
| Freeman, A | 1 |
| Gouider-Khouja, N | 1 |
| Ben Sassi, S | 1 |
| Ben Yahmed, S | 1 |
| Horvath, R | 1 |
| Kley, RA | 1 |
| Lochmüller, H | 1 |
| Vorgerd, M | 1 |
| Mariani, L | 1 |
| Miceli, R | 1 |
| Clementi, M | 1 |
| Stone, JT | 1 |
| Lin, CH | 1 |
| Dächsel, JC | 1 |
| Wu, RM | 1 |
| Fook-Chong, S | 2 |
| Yi, Z | 1 |
| White, LR | 1 |
| Kvam, SN | 1 |
| Aasly, JO | 1 |
| Huang, Y | 1 |
| Halliday, GM | 1 |
| Vandebona, H | 1 |
| Mellick, GD | 1 |
| Mastaglia, F | 1 |
| Stevens, J | 1 |
| Kwok, J | 1 |
| Garlepp, M | 1 |
| Silburn, PA | 1 |
| Horne, MK | 1 |
| Kotschet, K | 1 |
| Venn, A | 1 |
| Rowe, DB | 1 |
| Rubio, JP | 1 |
| Sue, CM | 1 |
| Borg, M | 1 |
| Ruberg, M | 1 |
| Zhao, Y | 1 |
| Lim, HQ | 1 |
| Lee, J | 1 |
| Yuen, Y | 1 |
| Pavanni, R | 1 |
| Wong, MC | 1 |
| Kalinderi, K | 1 |
| Fidani, L | 1 |
| Bostantjopoulou, S | 1 |
| Katsarou, Z | 1 |
| Kotsis, A | 1 |
| Munhoz, RP | 1 |
| Wakutani, Y | 1 |
| Teive, HA | 1 |
| Raskin, S | 1 |
| Werneck, LC | 1 |
| Moreno, D | 1 |
| Sato, C | 1 |
| An, XK | 1 |
| Wu, Y | 1 |
| Chen, WJ | 1 |
| Zhang, JH | 1 |
| Xu, YM | 1 |
| Gou, YR | 1 |
| Yuan, GG | 1 |
| Rademakers, R | 1 |
| Kachergus, JM | 1 |
| Nuytemans, K | 1 |
| Guidi, M | 1 |
| Riboldazzi, G | 1 |
| Brown, L | 1 |
| Walter, U | 1 |
| Benecke, R | 1 |
| Theuns, J | 1 |
| Pals, P | 1 |
| Cras, P | 1 |
| De Deyn, PP | 1 |
| Engelborghs, S | 1 |
| Pickut, B | 1 |
| Van Broeckhoven, C | 1 |
| Schägger, H | 1 |
| Carroll, CB | 1 |
| Holloway, V | 1 |
| Brotchie, JM | 1 |
| Mitchell, IJ | 1 |
| Ball, EF | 1 |
| Shaw, PJ | 1 |
| Ince, PG | 1 |
| Johnson, M | 1 |
| Youdim, MB | 1 |
| Jiménez-Jiménez, FJ | 1 |
| Molina, JA | 1 |
| Vargas, C | 1 |
| Gómez, P | 1 |
| Navarro, JA | 1 |
| Benito-León, J | 1 |
| Ortí-Pareja, M | 1 |
| Gasalla, T | 1 |
| Cisneros, E | 1 |
| Arenas, J | 1 |
| Dannhardt, G | 1 |
| Kohl, BK | 1 |
| Han, J | 1 |
| Cheng, FC | 1 |
| Yang, Z | 1 |
| Dryhurst, G | 1 |
| Lorenc-Koci, E | 1 |
| Iwasaki, Y | 1 |
| Ikeda, K | 1 |
| Shiojima, T | 1 |
| Kinoshita, M | 1 |
| Vamvakidès, A | 1 |
| Perschak, H | 1 |
| Amsler, U | 1 |
| Vischer, A | 1 |
| Siegfried, J | 1 |
| Cuénod, M | 1 |
| Gründig, E | 4 |
| Gerstenbrand, F | 3 |
| Oberhummer, J | 1 |
| Simanyi, M | 1 |
| Schedl, R | 1 |
| Weiss, J | 1 |
| McGeer, PL | 1 |
| McGeer, EG | 1 |
| Chase, TN | 1 |
| Woods, AC | 1 |
| Lipton, MA | 1 |
| Morris, CE | 1 |
| Kastin, AJ | 1 |
| Barbeau, A | 1 |
| Hanbauer, I | 1 |
| Bruck, J | 1 |
| Gnad, H | 1 |
| Prosenz, P | 1 |
| Teuflmayr, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The DNA and Cell Bank of IFR of Neurosciences: Clinical and Genetic Study of Parkinson's Disease and Epilepsies[NCT00142363] | 1,700 participants | Observational | 2004-05-31 | Terminated | |||
| Parkin Mutations and Their Functional Consequences[NCT00136721] | 2,500 participants | Observational | 2002-06-30 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
10 reviews available for glycine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
N-degron-mediated degradation and regulation of mitochondrial PINK1 kinase.
Topics: Animals; Glycine; Metabolic Networks and Pathways; Mitochondria; Mitochondrial Membranes; Mitochondr | 2020 |
In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
Topics: Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mitochondria; Mutation; Park | 2018 |
Glycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
Topics: Animals; Clinical Trials as Topic; Disease Models, Animal; Glycine; Humans; Parkinson Disease; Recep | 2013 |
LRRK2 G2019S in the North African population: a review.
Topics: Africa, Northern; Genetic Predisposition to Disease; Glycine; Humans; Leucine-Rich Repeat Serine-Thr | 2010 |
The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder.
Topics: Amygdala; Animals; Brain; Brain Mapping; Cataplexy; Emotions; gamma-Aminobutyric Acid; Glutamine; Gl | 2011 |
An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats.
Topics: Animals; Benzoates; Catalepsy; Corpus Striatum; Enkephalins; Excitatory Amino Acid Antagonists; Glut | 2007 |
LRRK2 low-penetrance mutations (Gly2019Ser) and risk alleles (Gly2385Arg)-linking familial and sporadic Parkinson's disease.
Topics: Alleles; Amino Acid Substitution; Asia; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protei | 2007 |
The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications.
Topics: Alzheimer Disease; Animals; Binding Sites; Cerebrovascular Disorders; Epilepsy; Glycine; Humans; Neu | 1998 |
[Working hypothesis for the effect of GABAergic, glycinergic or glutamatergic drugs in the treatment of Parkinson disease].
Topics: Animals; Antiparkinson Agents; gamma-Aminobutyric Acid; Glutamates; Glycine; Humans; Parkinson Disea | 1990 |
Neurotransmitter synthetic enzymes.
Topics: Acetylcholine; Acetyltransferases; Adenylyl Cyclases; Aging; Aminobutyrates; Animals; Brain; Brain C | 1973 |
1 trial available for glycine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Cysteine elevation in levodopa-treated patients with Parkinson's disease.
Topics: Adult; Aged; Analysis of Variance; Antiparkinson Agents; Cohort Studies; Cysteine; Female; Glycine; | 2009 |
103 other studies available for glycine and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Midbrain organoids mimic early embryonic neurodevelopment and recapitulate LRRK2-p.Gly2019Ser-associated gene expression.
Topics: Amino Acid Substitution; Amyloid beta-Protein Precursor; Carrier Proteins; Cell Differentiation; Cyt | 2022 |
The neuroprotective effects of FG-4592, a hypoxia-inducible factor-prolyl hydroxylase inhibitor, against oxidative stress induced by alpha-synuclein in N2a cells.
Topics: alpha-Synuclein; Glycine; Humans; Hypoxia; Neuroprotective Agents; Oxidative Stress; Parkinson Disea | 2023 |
Effect of Glycine on BV-2 Microglial Cells Treated with Interferon-γ and Lipopolysaccharide.
Topics: Alzheimer Disease; Animals; Antigens, CD; Apoptosis; Cell Line, Transformed; Glutathione; Glycine; H | 2020 |
Glycine nano-selenium prevents brain oxidative stress and neurobehavioral abnormalities caused by MPTP in rats.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Administration, Oral; Animals; Behavior, Animal; Brain | 2021 |
Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Family Health; Female; Gene Frequency; Genetic Predi | 2017 |
Clustering of motor and nonmotor traits in leucine-rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study.
Topics: Adult; Aged; Cohort Studies; Cross-Sectional Studies; Family; Family Health; Female; Glycine; Humans | 2018 |
Parkinsonism Relating to Intoxication with Glyphosate.
Topics: Adult; Glycine; Glyphosate; Herbicides; Humans; Levodopa; Magnetic Resonance Imaging; Male; Muscle R | 2019 |
Basal and Evoked Neurotransmitter Levels in Parkin, DJ-1, PINK1 and LRRK2 Knockout Rat Striatum.
Topics: Acetylcholine; Animals; Brain; Dopamine; Dopaminergic Neurons; gamma-Aminobutyric Acid; Gene Knockou | 2019 |
Specific pesticide-dependent increases in α-synuclein levels in human neuroblastoma (SH-SY5Y) and melanoma (SK-MEL-2) cell lines.
Topics: alpha-Synuclein; Cell Death; Cell Line, Tumor; Cell Survival; Glycine; Glyphosate; Humans; Insectici | 2013 |
Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Brain; Female; Gene Expression Regulation; Glycine; Humans | 2013 |
LRRK2 G2385R variant carriers of female Parkinson's disease are more susceptible to motor fluctuation.
Topics: Aged; Female; Genotype; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male | 2013 |
Parkinson disease phenotype in Ashkenazi Jews with and without LRRK2 G2019S mutations.
Topics: Aged; Female; Genotype; Glycine; Humans; Jews; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2013 |
The G2019S LRRK2 mutation: another morbid burden for Ashkenazi Jews may provide new insights on sporadic Parkinson's disease.
Topics: Female; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Male; Mutation; Park | 2013 |
A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers.
Topics: Adult; Brain; Cognition Disorders; Diffusion Tensor Imaging; Female; Glycine; Humans; Leucine-Rich R | 2014 |
(G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
Topics: Animals; Apomorphine; Cerebral Cortex; Corpus Striatum; Dopamine Agonists; Dopaminergic Neurons; GAB | 2014 |
Motor progression of Parkinson's disease with the leucine-rich repeat kinase 2 G2019S mutation.
Topics: Aged; Disease Progression; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Glyc | 2014 |
Cognitive dysfunction in Parkinson's disease related to the R1441G mutation in LRRK2.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Case-Control Studies; Cognition Disorders; Female; Glycine | 2014 |
Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.
Topics: Aged; Aged, 80 and over; Europe; Female; Genetic Association Studies; Genetic Predisposition to Dise | 2015 |
Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Topics: Adenoviridae; alpha-Synuclein; Animals; Corpus Striatum; Disease Models, Animal; Female; Forelimb; G | 2015 |
Olfactory Dysfunction in Parkinson's Disease Patients with the LRRK2 G2385R Variant.
Topics: Aged; Aged, 80 and over; Arginine; Female; Genetic Predisposition to Disease; Genotype; Glycine; Hum | 2016 |
Association of the DRD2 CA
Topics: Aged; Aged, 80 and over; Analysis of Variance; Benzothiazoles; Case-Control Studies; Dinucleotide Re | 2017 |
Heart rate variability in leucine-rich repeat kinase 2-associated Parkinson's disease.
Topics: Aged; Electrocardiography; Female; Genetic Association Studies; Glycine; Heart Diseases; Heart Rate; | 2017 |
Parkinson patient fibroblasts show increased alpha-synuclein expression.
Topics: Aged; alpha-Synuclein; Aspartic Acid; Cells, Cultured; Family Health; Female; Fibroblasts; Gene Expr | 2008 |
LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
Topics: Age Factors; Case-Control Studies; Gene Frequency; Genetic Predisposition to Disease; Genotype; Glyc | 2008 |
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
Topics: Age Factors; Age of Onset; Case-Control Studies; DNA Mutational Analysis; Family Health; Female; Gen | 2008 |
LRRK2: bridging the gap between sporadic and hereditary Parkinson's disease.
Topics: Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinson Disease; | 2008 |
Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy.
Topics: Adult; Age of Onset; Aged; DNA Mutational Analysis; Female; Fluorodeoxyglucose F18; Gene Frequency; | 2009 |
A clinical, neuropsychological and olfactory evaluation of a large family with LRRK2 mutations.
Topics: Aged; DNA Mutational Analysis; Family Health; Female; France; Genetic Predisposition to Disease; Gly | 2009 |
LRRK2 gene G2019S mutation and SNPs [haplotypes] in subtypes of Parkinson's disease.
Topics: Age of Onset; Aged; Aged, 80 and over; DNA Mutational Analysis; Female; Gene Frequency; Genetic Pred | 2009 |
Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Arginine; Cysteine; DNA Mutational Analysis; Female; Ge | 2009 |
LRRK2 mutations in Basque patients with Parkinson's disease.
Topics: Arginine; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mutation; Parkinso | 2008 |
The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study.
Topics: Age Factors; Aged; Aged, 80 and over; Female; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine | 2008 |
Multiple step pattern as a biomarker in Parkinson disease.
Topics: Aged; Analysis of Variance; Attention; Biomarkers; Female; Fixation, Ocular; Glycine; Humans; Leucin | 2009 |
LRRK2 mutations and risk variants in Japanese patients with Parkinson's disease.
Topics: Aged; Arginine; DNA Mutational Analysis; Exons; Family Health; Female; Gene Frequency; Genetic Predi | 2009 |
Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Community Networks; Dyskinesia, Drug-Induced; Female; | 2009 |
The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Chi-Square Distribution; Female; Gene Frequency; Genetic P | 2010 |
ATP13A2 G2236A variant is rare in patients with early-onset Parkinson's disease and familial Parkinson's disease from Mainland China.
Topics: Age of Onset; Alanine; China; DNA Mutational Analysis; Glycine; Humans; Parkinson Disease; Polymorph | 2010 |
Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment.
Topics: Aged; Aged, 80 and over; alpha-Synuclein; Cerebral Cortex; Cognition Disorders; Electrophoresis, Gel | 2010 |
LRRK2 Gly2385Arg polymorphism, cigarette smoking, and risk of sporadic Parkinson's disease: a case-control study in Japan.
Topics: Aged; Arginine; Case-Control Studies; Female; Gene Frequency; Genetic Predisposition to Disease; Gen | 2010 |
Penetrance in Parkinson's disease related to the LRRK2 R1441G mutation in the Basque country (Spain).
Topics: Age Factors; Aged; Aged, 80 and over; Arginine; Family; Female; Glycine; Humans; Incidence; Leucine- | 2010 |
Evidence of D-phenylglycine as delivering tool for improving L-dopa absorption.
Topics: Animals; Biological Availability; Chromatography, High Pressure Liquid; Dopamine; Drug Carriers; Gly | 2010 |
Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3.
Topics: Aged; Aged, 80 and over; Alanine; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Biomarkers; Case | 2010 |
123I-MIBG cardiac uptake and smell identification in parkinsonian patients with LRRK2 mutations.
Topics: 3-Iodobenzylguanidine; Adult; Aged; Aged, 80 and over; Female; Glycine; Heart; Humans; Leucine-Rich | 2011 |
Substantia nigra hyperechogenicity with LRRK2 G2019S mutations.
Topics: Adult; Age Factors; Aged; Female; Genetic Predisposition to Disease; Glycine; Humans; Leucine-Rich R | 2011 |
LRRK2 G2019S mutations may be increased in Puerto Ricans.
Topics: Adult; Aged; Female; Glycine; Hispanic or Latino; Humans; Leucine-Rich Repeat Serine-Threonine Prote | 2011 |
Mood and cognition in leucine-rich repeat kinase 2 G2019S Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cognition Disorders; Female; Genetic Predisposition to Disease; Glycine; Hu | 2011 |
Kin-cohort analysis of LRRK2-G2019S penetrance in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Cohort Studies; DNA Mutational Analysis; Family Health; Female; Glycine; Hu | 2011 |
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Gene Freq | 2012 |
[The absence of the common LRRK2 G2019S mutation in 120 young onset Hungarian Parkinon's disease patients].
Topics: Adult; Age of Onset; Aged; Female; Gene Frequency; Genetic Predisposition to Disease; Genetic Testin | 2012 |
Olfaction and imaging biomarkers in premotor LRRK2 G2019S-associated Parkinson disease.
Topics: Aged; Aged, 80 and over; Biomarkers; Chi-Square Distribution; Cohort Studies; Cross-Sectional Studie | 2013 |
Mitochondrial DNA A4336G mutation in Alzheimer's and Parkinson's diseases.
Topics: Aged; Alanine; Alzheimer Disease; Case-Control Studies; DNA, Mitochondrial; Female; Glycine; Humans; | 2002 |
Distinct functional roles of the metabotropic glutamate receptors 1 and 5 in the rat globus pallidus.
Topics: Animals; Cells, Cultured; Central Nervous System; Electric Conductivity; Enzyme Inhibitors; Excitato | 2003 |
Polymorphisms of the alpha-synuclein promoter: expression analyses and association studies in Parkinson's disease.
Topics: Aged; alpha-Synuclein; Cell Culture Techniques; Cysteine; Enzyme-Linked Immunosorbent Assay; Female; | 2003 |
Clinical characteristics of the alpha-synuclein mutation (G209A)-associated Parkinson's disease in comparison with other forms of familial Parkinson's disease in Greece.
Topics: Age of Onset; Aged; Aged, 80 and over; Alanine; alpha-Synuclein; DNA Mutational Analysis; Family Hea | 2003 |
The E318G substitution in PSEN1 gene is not connected with Alzheimer's disease in a large Polish cohort.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Chi-Square Distribution; Cohort St | 2004 |
Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.
Topics: Aged; Amino Acid Sequence; Animals; Dihydroxyphenylalanine; DNA Mutational Analysis; Family Health; | 2005 |
Gene mutation detected in Parkinson's disease.
Topics: Amino Acid Substitution; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mut | 2005 |
Chronic treatment with the mGlu5R antagonist MPEP reduces the functional effects of the mGlu5R agonist CHPG in the striatum of 6-hydroxydopamine-lesioned rats: possible relevance to the effects of mGlu5R blockade in Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Denervation; Drug Interactions; Ex | 2005 |
Genetic testing in Parkinson's disease.
Topics: Female; Genetic Testing; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Mal | 2005 |
Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Female; Follow-Up Studies; G | 2005 |
G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort.
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; DNA Mutational Analysis; Family Health; Female; Gene | 2005 |
G2019S LRRK2 mutation in French and North African families with Parkinson's disease.
Topics: Adult; Africa, Northern; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Female; Fr | 2005 |
Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Fe | 2006 |
Biochemical and pathological characterization of Lrrk2.
Topics: Adult; Aged; Aged, 80 and over; alpha-Synuclein; Amino Acid Sequence; Animals; Blotting, Western; Br | 2006 |
LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.
Topics: Adolescent; Adult; Age of Onset; Aged; Aged, 80 and over; Arginine; Child; Child, Preschool; DNA Mut | 2006 |
Prevalence of the LRRK2 G2019S mutation in a UK community based idiopathic Parkinson's disease cohort.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Chromosome Aberrations; Cohort Studies; DNA | 2006 |
Clinical heterogeneity of the LRRK2 G2019S mutation.
Topics: Aged; Aged, 80 and over; Case-Control Studies; DNA Mutational Analysis; Female; Glycine; Humans; Leu | 2006 |
Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations.
Topics: Aged; DNA Mutational Analysis; Family Health; Female; Gene Frequency; Genetic Predisposition to Dise | 2006 |
Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques.
Topics: Aged; Arginine; Chromosomes, Human, Pair 12; Demography; DNA Mutational Analysis; Family Health; Fem | 2006 |
G2019S LRRK2 mutation in familial and sporadic Parkinson's disease in Russia.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Female; Glycine; Humans; Leu | 2006 |
Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Family Health; Female; Genetic Testing; Glycine; Humans; | 2006 |
LRRK2 G2019S founder haplotype in the Chinese population.
Topics: Asian People; Glycine; Haplotypes; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2; Pa | 2007 |
Global distribution and reduced penetrance: Lrrk2 R1441C in an Irish Parkinson's disease kindred.
Topics: Arginine; Binding Sites; Disease Progression; Glycine; Histidine; Humans; Ireland; Leucine-Rich Repe | 2007 |
Genetic analysis of LRRK2 mutations in patients with Parkinson disease.
Topics: Adult; Aged; Arginine; Chromosomes, Human, Pair 12; DNA Mutational Analysis; Female; Glycine; Humans | 2006 |
Screening for Lrrk2 G2019S and clinical comparison of Tunisian and North American Caucasian Parkinson's disease families.
Topics: Adult; Aged; Aged, 80 and over; Cross-Cultural Comparison; DNA Mutational Analysis; Family Health; F | 2007 |
Parkinson syndrome, neuropathy, and myopathy caused by the mutation A8344G (MERRF) in tRNALys.
Topics: Aged; Alanine; Amino Acid Substitution; Glycine; Humans; Male; MERRF Syndrome; Muscle, Skeletal; Mus | 2007 |
Evaluation of LRRK2 G2019S penetrance: relevance for genetic counseling in Parkinson disease.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; DNA Mutational Analysis; Family Health; Female; Geneti | 2007 |
Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia.
Topics: Aged; Arginine; Asian People; Female; Genetic Predisposition to Disease; Glycine; Humans; Leucine-Ri | 2007 |
Comparing LRRK2 Gly2385Arg carriers with noncarriers.
Topics: Aged; Arginine; Female; Genetic Carrier Screening; Glycine; Humans; Leucine-Rich Repeat Serine-Threo | 2007 |
MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease.
Topics: Aged; Aged, 80 and over; DNA Mutational Analysis; Female; Genetic Predisposition to Disease; Glycine | 2007 |
Prevalence and clinical features of common LRRK2 mutations in Australians with Parkinson's disease.
Topics: Aged; Australia; Cohort Studies; DNA Mutational Analysis; Family Health; Female; Genetic Predisposit | 2007 |
Frequency of the LRRK2 G2019S mutation in siblings with Parkinson's disease.
Topics: Aged; DNA Mutational Analysis; Europe; Family Health; Female; Glycine; Humans; Leucine-Rich Repeat S | 2007 |
Analysis of LRRK2 Gly2385Arg genetic variant in non-Chinese Asians.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Asia, Southeastern; Chi-Square Distribution; Female; Gene | 2007 |
The G2019S LRRK2 mutation is uncommon amongst Greek patients with sporadic Parkinson's disease.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Cohort Studies; Female; Glycine; Greece; Humans; L | 2007 |
The G2019S LRRK2 mutation in Brazilian patients with Parkinson's disease: phenotype in monozygotic twins.
Topics: Adult; Age of Onset; Aged; Aged, 80 and over; Brazil; Diseases in Twins; Female; Glycine; Humans; Le | 2008 |
LRRK2 Gly2385Arg variant is a risk factor of Parkinson's disease among Han-Chinese from mainland China.
Topics: Adult; Aged; Aged, 80 and over; Arginine; Asian People; Chi-Square Distribution; China; Female; Gene | 2008 |
Uniting Chinese across Asia: the LRRK2 Gly2385Arg risk variant.
Topics: Arginine; Asia; Asian People; Glycine; Humans; Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 | 2008 |
Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson disease.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Arginine; Cysteine; DNA Mutational Analysis | 2008 |
Quantification of oxidative phosphorylation enzymes after blue native electrophoresis and two-dimensional resolution: normal complex I protein amounts in Parkinson's disease conflict with reduced catalytic activities.
Topics: Electrophoresis, Gel, Two-Dimensional; Electrophoresis, Polyacrylamide Gel; Glycine; Humans; NAD(P)H | 1995 |
Neurochemical and behavioural investigations of the NMDA receptor-associated glycine site in the rat striatum: functional implications for treatment of parkinsonian symptoms.
Topics: 2-Amino-5-phosphonovalerate; Animals; Behavior, Animal; Binding, Competitive; Corpus Striatum; Dose- | 1995 |
The distribution of excitatory amino acid receptors in the normal human midbrain and basal ganglia with implications for Parkinson's disease: a quantitative autoradiographic study using [3H]MK-801, [3H]glycine, [3H]CNQX and [3H]kainate.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Autoradiography; Basal Ganglia; Binding Sites; Dizocilpine Mal | 1994 |
Parkinson's disease and milacemide.
Topics: Acetamides; Animals; Brain; Glycine; Humans; Macaca mulatta; Monoamine Oxidase Inhibitors; Motor Ski | 1994 |
Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease.
Topics: Aged; Amino Acids; Asparagine; Aspartic Acid; Female; gamma-Aminobutyric Acid; Glutamic Acid; Glutam | 1996 |
Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; Animals; Corpus Striatum; | 1999 |
The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity.
Topics: Animals; Bridged Bicyclo Compounds; Electromyography; Glycine; Ligands; Male; Muscle Rigidity; Parki | 2000 |
Increased plasma concentrations of aspartate, glutamate and glycine in Parkinson's disease.
Topics: Aged; Aged, 80 and over; Aspartic Acid; Female; Glutamates; Glutamic Acid; Glycine; Humans; Male; Mi | 1992 |
Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders.
Topics: Adult; Aged; Amino Acids; Aspartic Acid; Ethanolamine; Ethanolamines; Female; gamma-Aminobutyric Aci | 1987 |
[Biochemical aspects of the effect of L-dopa in patients with Parkinson's disease].
Topics: Cysteine; Cystine; Dihydroxyphenylalanine; Female; Glycine; Humans; Male; Methionine; Parkinson Dise | 1972 |
Hypothalamic releasing factors and Parkinson disease.
Topics: Antiparkinson Agents; Depression, Chemical; Dihydroxyphenylalanine; Drug Therapy, Combination; Glyci | 1974 |
Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
Topics: Administration, Oral; Aged; Amides; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Glycine; H | 1972 |
[Correlation between Parkinsonism symptoms and a disorder in the amino acid metabolism in CNS].
Topics: Amino Acids; Animals; Brain Injuries; Central Nervous System Diseases; Cerebrospinal Fluid; Cysteine | 1970 |
[Brain aminoacids in phenothiazin-induced Parkinsonism. Drug-induced parkinsonism in the rat--a model for biochemical studies of the Parkinson-syndrome].
Topics: Amino Acids; Aminobutyrates; Animals; Basal Ganglia; Brain; Cerebellum; Cerebral Cortex; Chromatogra | 1970 |
[The effect of the administration of amino acids, especially of L-dopa and alpha-methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. I. Alterations of cerebrospinal fluid in patients with parkinson's disease and normals].
Topics: Alanine Transaminase; Arginine; Aspartate Aminotransferases; Dihydroxyphenylalanine; Glutamine; Glyc | 1969 |